Solengepras, a new daily pill developed by Cerevance, has completed a late-stage phase three clinical trial, significantly reducing “off” time and movement symptoms for Parkinson’s disease patients. The non-dopaminergic treatment offers a fresh therapeutic pathway for the 150,000 Australians and 166,000 individuals in the UK living with the condition.
Clinical Trial Efficacy and Trial Demographics
The randomized, double-blind, placebo-controlled trial evaluated 341 patients across the US, Europe, the UK, and Australia. Participants took either 75mg or 150mg of solengepras or a placebo once daily for 12 weeks alongside their existing dopamine medications.
Patients in the higher-dose solengepras group experienced nearly 37 minutes less daily “off” time—periods when standard dopamine therapies lose efficacy—compared to the placebo group. This equated to roughly an hour-and-a-half reduction in daily “off” time compared to baseline measurements before the trial.
| Trial Metric | Solengepras (Higher Dose) vs. Placebo |
|---|---|
| Daily “Off” Time Reduction | ~37 minutes less per day |
| Extra “On” Time Without Dyskinesia | ~36 extra minutes per day |
| Trial Duration | 12 weeks |
| Participant Sample Size | 341 patients (US, Europe, UK, Australia) |
Solengepras Inhibits GPR6 to Bypass Dopamine Pathway
For over fifty years, mainstream Parkinson’s treatments have focused almost exclusively on dopamine, the neurotransmitter deficient in patients due to dying brain cells. While medications like Levodopa help replace this chemical messenger, their efficacy diminishes as the degenerative condition advances, frequently triggering dyskinesia—involuntary twisting or jerking movements—alongside nausea and hallucinations.
Solengepras bypasses the dopamine pathway entirely. Instead, the drug inhibits GPR6, a specific receptor located within a brain circuit that functions like a brake on movement. By blocking this receptor, solengepras reduces the overly strong braking effect caused by dopamine deficiency, helping to restore motor balance without targeting the dopamine neurotransmitter system directly.
Solengepras Targets GPR6 to Reduce off Time
- A New Pathway: Solengepras targets a brain receptor called GPR6 rather than relying on dopamine, offering a completely different way to manage physical symptoms.
- Less “Off” Time: Patients taking the higher dose gained roughly 36 extra minutes of smooth daily movement free from involuntary jerking motions.
- Manageable Side Effects: The medication was generally well-tolerated during the 12-week trial, with reported adverse events primarily limited to headaches and urinary tract infections.
Funding, Regulatory Next Steps, and Patient Access
Cerevance, a US clinical-stage biopharmaceutical company supported by SV Health Investors, developed the medication. Dame Kate Bingham, managing partner at SV Health Investors, described the treatment as an entirely new class beyond the dopamine pathway. Laurence Barker, a partner at SV Health Investors and a board member of Cerevance, noted that this represents the first positive phase three study for a non-dopaminergic mechanism for a very long time.
Following the successful trial completion, Cerevance plans to discuss the findings with the US Food and Drug Administration (FDA) to determine subsequent regulatory milestones. Health authorities must review the safety and efficacy data before the pill can secure marketing authorization. If regulatory reviews proceed without delay, solengepras could become available to patients within two to three years.
Solengepras Awaits Regulatory Approval for Prescription
Parkinson’s disease presents complex motor fluctuations that require close clinical supervision. Because solengepras is still undergoing regulatory review, it is not yet approved for public prescription.
References
- The Times (Coverage on Cerevance clinical trial milestones and non-dopaminergic therapeutic classes)
- Parkinson’s Australia (Epidemiological prevalence data for neurological conditions)
- Parkinson’s UK (UK diagnostic statistics and national health insights)
